Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables - Net: 2013-2024

Historic Receivables - Net for Ptc Therapeutics (PTCT) over the last 12 years, with Dec 2024 value amounting to $158.6 million.

  • Ptc Therapeutics' Receivables - Net rose 1.55% to $203.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.1 million, marking a year-over-year increase of 1.55%. This contributed to the annual value of $158.6 million for FY2024, which is 1.41% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Receivables - Net is $158.6 million, which was down 1.41% from $160.8 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Receivables - Net peaked at $160.8 million during FY2023, and registered a low of $69.9 million during FY2020.
  • Over the past 3 years, Ptc Therapeutics' median Receivables - Net value was $158.6 million (recorded in 2024), while the average stood at $158.3 million.
  • Per our database at Business Quant, Ptc Therapeutics' Receivables - Net soared by 57.95% in 2021 and then decreased by 1.41% in 2024.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Receivables - Net stood at $69.9 million in 2020, then surged by 57.95% to $110.5 million in 2021, then surged by 40.88% to $155.6 million in 2022, then rose by 3.35% to $160.8 million in 2023, then decreased by 1.41% to $158.6 million in 2024.